MedTrace Logo

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

NCT00760981 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-04-15

No results posted yet for this study

Summary

To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and whether their cGVHD responds to imatinib mesylate.

Conditions

  • Graft vs Host Disease

Interventions

DRUG

Imatinib

The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • David Miklos

    lead OTHER

Principal Investigators

  • David Miklos, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2012-04-30
Completion
2012-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760981 on ClinicalTrials.gov